The FDA commissioner has suggested that "smarter" and real-time clinical trials could significantly impact drug development. The FDA appears to be taking steps to implement such trials, potentially using artificial intelligence, with some reports indicating a pilot program is being launched with certain pharmaceutical companies. However, the scope and details of the FDA's efforts are not entirely clear, with some reports focusing on broader trends in drug development and the use of AI in the field.